

Prefixes, infixes, and suffixes for monoclonal antibody nomenclature (generic names)					
Prefix	Target infix		Source infix		Suffix
<i>Varies, "should be euphonious"</i>	<b>-o(s)-</b>	bone	<b>-u-</b>	human	<b>-mab</b>
	<b>-v(i)-</b>	viral	<b>-o-</b>	mouse	
	<b>-b(a)-</b>	bacterial	<b>-a-</b>	rat	
	<b>-l(i)-</b>	immunomodulating	<b>-e-</b>	hamster	
	<b>-c(i)-</b>	cardiovascular	<b>-i-</b>	primate	
	<b>-k(i)-</b>	interleukin as target	<b>-xi-</b>	chimeric	
	<b>-t(u)-</b>	miscellaneous tumor	<b>-zu-</b>	humanized	
	<b>-tox(a)-</b>	toxin as target	<b>-axo-</b>	rat/mouse hybrid	
<b>-f(u)-</b>	fungal				

from WHO Guidelines 2009, which are simpler than the 1999 version

Letters in parenthesis are used when a consonant would run into another: So, not efalzumab, but efalizumab: **efa** + **li** (immune) + **zu** (humanized) + **mab** (mAb to CD11a)

e.g. adalimumab: **ada** + **lim** (immunomodulating) + **u** (human) + **mab** (mAb to TNF $\alpha$ ); was named according to older guidelines, would today be named **adalumab**

**ASK YOURSELF:** Oxo Corporation has made a mAb by combining one set of variable regions from a mouse and one from a rat; it's against two rattlesnake venom epitopes. What shall they name it?